Despite the urgent, unmet clinical and economic need for treatment of ALS, trials of disease‐modifying drugs have produced little success. Recently, edaravone, a neuroprotective drug that has properties of a free radical scavenger, was the second drug to be approved by the FDA for ALS therapy (Hardiman & van den Berg, 2017; Mora, 2017; Sawada, 2017). Whereas a double‐blinded placebo‐controlled phase 2 study using intravenous edaravone therapy in patients with ALS failed to show a significant difference between treated and control patients, a small subset of patients did in fact show benefit (Writing & Edaravone, 2017). Thus, there is still a large population without any disease‐modifying agent (Mora, 2017).